Terapia ewerolimusem u pacjenta z zaawansowanym nowotworem neuroendokrynnym trzustki – opis przypadku
Journal Title: OncoReview - Year 2012, Vol 2, Issue 3
Abstract
Coraz częstsze występowanie nowotworów neuroendokrynnych przewodu pokarmowego jest spowodowane nie tylko rzeczywistym wzrostem zachorowalności, ale także postępem w zakresie ich diagnostyki. Właściwe rozpoznanie oraz ocena stopnia zaawansowania choroby pozwalają określić rokowanie oraz wybrać optymalny schemat leczenia. Przedstawiony przypadek kliniczny chorego z zaawansowanym nowotworem neuroendokrynnym trzustki leczonego ewerolimusem dowodzi skuteczności terapii celowanej.
Authors and Affiliations
Bogumiła Czartoryska-Arłukowicz
Keywords
Related Articles
- EP ID EP53175
- DOI -
- Views 248
- Downloads 0
Application of echocardiography in oncology – practical remarks
The paper presents the contemporary use of echocardiography in diagnosis of primary and metastatic tumors of the heart as well as in assessment of cardiovascular risk related to medical and interventional oncological the...
The mTOR signalling pathways in the pathogenesis and treatment of neuroendocrine tumours
Neuroendocrine tumours (NET) are a rare and heterogeneous group of neoplasms.The majority of patients are diagnosed with locally advanced or metastatic disease, and curative surgery is rarely an option. Treatment approac...
Nuclear medicine diagnostic tools for early detection of myocardial damage in treated breast cancer patients
The most severe side effect in treated patients with breast cancer is treatment-induced cardiotoxicity, leading to chronic heart failure or CAD, and worsening the patient’s quality of life. The early detection and medica...
Novel oral anticoagulants in the treatment of cancer patients
Cancer and its treatment are well-recognized risk factors for venous thromboembolism. The risk of thrombotic complications increases 4–7-fold in cancer patients and coexistence of both pathologies is associated with shor...
Imaging techniques used to detect oncological treatment complications
Oncological drugs are toxic for the cardiovascular system, directly affecting cardiac function and anatomy. Oncological treatment complications may thus take the form of asymptomatic myocardial dysfunction, overt heart f...